Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04100018 · ClinicalTrials.gov registry record · Phase 3
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,030
- Enrollment target
NCT04100018 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 1,030 participants.
The verdict
NCT04100018, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,030 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Interventions
- DRUG Docetaxel
- OTHER Placebo
- DRUG Prednisone
- BIOLOGICAL Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,030 participants |
| Start Date | 2020-02-06 |
| Est. Completion | 2024-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04100018
The ClinicalTrials.gov registry entry for NCT04100018 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,030 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Docetaxel is the first listed.
NCT04100018 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04100018 about?
NCT04100018 is a clinical study titled "A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer". The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
What is the current status of trial NCT04100018?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,030 participants. The study started on 2020-02-06. Estimated completion is 2024-06-25.
What interventions are being tested in trial NCT04100018?
The interventions under investigation include: Docetaxel (DRUG), Placebo (OTHER), Prednisone (DRUG), Nivolumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04100018?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.